We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Postpones Decision on Novo Nordisk’s Diabetes Candidate IDegLira
FDA Postpones Decision on Novo Nordisk’s Diabetes Candidate IDegLira
The FDA has extended the review period for Novo Nordisk’s Type 2 diabetes candidate IDegLira, just weeks after the agency delayed its decision on a comparable therapy by Sanofi.